However, in the recent decade, greater emphasis on molecular biomarkers such as MSI, KRAS, BRAF, and CDX2 and histological features such as tumour budding, TILS, CRM, PNI, LVI, apical lymph node involvement, LNY, and LNR has allowed better characterisation of the tumour, improving the accuracy of prognostication as well as the optimisation of neoadjuvant and adjuvant treatment. Here, CDX2 is linked to neoplasm.